Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...
The 3-year local recurrence rate was 3.6% for transanal TME and 4.4% for laparoscopic TME. The 3-year overall survival was 92 ...
The Centre’s decision to significantly slash the income tax payer’s burden was aimed at addressing some “angst” that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback